Search the Newsreel

Aquestive Therapeutics Q2 Earnings Call Highlights

Key Points Interested in Aquestive Therapeutics, Inc.? Here are five stocks we like better. Aquestive plans to resubmit Anaphylm's FDA application before the end of Q3 after revised packaging and instructions substantially reduced pouch-opening, film-tearing and administration errors in validation studies. Management is assuming …

Celestica, Inc. (CLS) News, Articles, Events & Latest Updates

This article provides recent news and updates concerning Celestica, Inc. (CLS), highlighting its equity offerings to fund AI infrastructure growth and its position as a top-ranked growth stock. It also features analysis comparing Celestica to its competitor Flex, discussing the impact of AI on …

Earnings call transcript: Aquestive Therapeutics tops revenue views in Q2 2026

Aquestive Therapeutics reported Q2 2026 revenue of $13.82 million, exceeding analyst estimates, but also posted a wider-than-expected loss of $0.18 per share due to an $11.7 million debt extinguishment charge. The company remains on track to resubmit its Anaphylm NDA to the FDA in …

Stifel raises Vestis stock price target to $14 on turnaround progress

Stifel increased its price target for Vestis Corp (NYSE:VSTS) to $14 from $11, maintaining a Hold rating, citing progress in the company's operational turnaround. Despite a significant stock surge, InvestingPro analysis suggests the shares may be overvalued. Key factors for the price target adjustment …

Vestis (NYSE:VSTS) Stock Rating Lowered by Zacks Research

Zacks Research has downgraded Vestis (NYSE:VSTS) from a "strong buy" to a "hold" rating, contributing to an overall analyst consensus of "reduce" with an average price target of $9.50. Despite Vestis beating EPS estimates with $0.18 for the quarter, its revenue of $661.7 million …

Prestige Consumer Healthcare (NYSE:PBH) Upgraded by Zacks Research to "Hold" Rating

Zacks Research has upgraded Prestige Consumer Healthcare (NYSE:PBH) from a "strong sell" to a "hold" rating. This upgrade comes after the company exceeded quarterly earnings expectations, reporting $0.98 EPS against a $0.89 consensus and revenue of $265.71 million, a 6.5% increase year-over-year. The consensus …

First Majestic Silver Corp. $AG Shares Sold by NewEdge Advisors LLC

NewEdge Advisors LLC decreased its holdings in First Majestic Silver Corp. (NYSE:AG) by 25.5% in the first quarter, selling over 75,000 shares but still retaining a significant stake valued at approximately $4.74 million. Despite the company reporting strong revenue growth of 57.3% year-over-year, it …

Have Insiders Sold First Majestic Silver Shares Recently?

The Founder of First Majestic Silver Corp., Keith Neumeyer, recently sold CA$690k worth of stock, reducing his total holding by 0.6%. While there have been more insider sales than purchases over the past year, the company still boasts high insider ownership of 1.1% (CA$138m). …

Vestis Q3 Earnings Call Highlights

Vestis (NYSE: VSTS) reported its fiscal Q3 results, showing improved profitability and cash generation despite a revenue decline of 1.8% to $662 million, attributed to exiting lower-margin business. Net income reached $11 million, and adjusted EBITDA increased by 26% to $80.9 million, with margins …

Vestis forecasts $160M-$170M fiscal 2026 free cash flow while outlining network “quadrant” focus for 2027

Earnings Call Insights: Vestis Corporation (VSTS) Q3 fiscal 2026 MANAGEMENT VIEW * “Our third quarter results highlight consistent execution of our transformation plan,” said CEO, President & Director James Barber, adding, “for the second quarter in a row, we grew adjusted EBITDA year-over-year and …

Vestis (VSTS) Stock Stalls As Profit Returns But Revenue Slips

Aquestive Therapeutics Q2 Loss Widens, Revenue Rises

Aquestive Therapeutics reported a wider net loss in Q2 compared to the previous year, despite an increase in total revenue. The company also updated its full-year 2026 outlook, anticipating total revenue to be between $58 million and $62 million, with non-GAAP adjusted EBITDA expected …

Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates

Form 8K Vestis Corp For: 11 August By Investing.com

This article from Investing.com reports the filing of a Form 8K by Vestis Corp on August 11. It's a concise announcement about the regulatory filing, indicating an important corporate event. The article itself is very brief, primarily serving as a notification.

Vestis Repays $30M of Debt After Generating $47M in Cash Flow

Vestis Corporation (NYSE: VSTS) reported strong fiscal third quarter 2026 results, generating $47.0 million in Free Cash Flow and using $30 million of it to repay debt. The company also increased its full-year 2026 Free Cash Flow outlook by 22% to a range of …

Aquestive Therapeutics (NASDAQ:AQST) Releases Earnings Results, Misses Expectations By $0.08 EPS

Aquestive Therapeutics: Q2 Earnings Snapshot

This article provides a brief "Q2 Earnings Snapshot" for Aquestive Therapeutics. It is a very short piece, indicating that the company's Q2 earnings were reported.

Aquestive Therapeutics (AQST) grows revenue and refinances debt in Q2 2026

Aquestive Plans to Take Epi Film Back to FDA with Positive Data

Aquestive Therapeutics plans to resubmit its drug application for Anaphylm, an oral dissolving film for severe allergic reactions, to the FDA this fall. This follows the completion of two additional studies requested by the FDA, which have yielded positive results regarding revised packaging, ease …

Vestis (NYSE:VSTS) Stock Price Down 5.6% - Time to Sell?

Vestis (NYSE:VSTS) stock dropped 5.6% to $13.09, trading below its 50-day moving average and experiencing lower-than-average trading volume. Despite beating quarterly EPS estimates, the company missed revenue expectations, and analyst sentiment is largely negative with an average "Reduce" rating and a price target well …

Aquestive Therapeutics (NASDAQ:AQST) Shares Up 7.1% - Here's Why

Aquestive Therapeutics (NASDAQ:AQST) saw its shares rise 7.1% to $4.595, with a market capitalization of approximately $574 million. The company's stock holds a consensus "Buy" rating from analysts with an average price target of $8.50, driven by its recent beat on quarterly earnings expectations. …

Earnings call transcript: Vestis misses Q3 2026 estimates as cash flow improves

Vestis (VSTS) reported Q3 2026 earnings and revenue well below analyst estimates, with adjusted EPS at $0.18 against an expected $0.50, and revenue of $661.7 million versus $834.2 million forecast. Despite the misses, the company highlighted improved profitability, cash flow, and pricing, leading to …

Vestis Corporation 2026 Q3 - Results - Earnings Call Presentation (NYSE:VSTS) 2026-08-11

Vestis Corporation Q3 2026 Earnings Call Summary - Moby Strategic Transformation and Operational Execution Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. …

DXYZ Price Today: Destiny Tech100 Inc. Stock Price, Quote & Chart | MEXC

Why is Vestis stock rallying today?

Vestis Corp's stock rallied by 5.5% in pre-market trading despite missing Q3 revenue and earnings estimates. The surge was driven by the company's decision to raise its full-year fiscal 2026 free cash flow guidance to $160 million to $170 million, indicating improved capital efficiency …

CLS Looks 125.6% Overvalued on GF Value™

Celestica Inc (NYSE: CLS) is significantly overvalued according to GuruFocus's GF Value™, trading 125.6% above its intrinsic value. Despite a strong GF Score™ of 84/100, driven by excellent growth and momentum, its valuation rank is low, and insider selling contrasts with guru accumulation. Investors …

Scotiabank Reaffirms "Sector Outperform" Rating for Celestica (NYSE:CLS)

Scotiabank has reiterated its "Sector Outperform" rating for Celestica (NYSE:CLS) and maintained a $500 price target, suggesting a 58.79% upside. This follows Celestica's strong quarterly earnings, which surpassed consensus estimates for both EPS and revenue. Analysts collectively rate the stock as a "Moderate Buy" …

Vestis (NYSE:VSTS) Reports Sales Below Analyst Estimates In Q2 CY2026 Earnings

Vestis (VSTS) reported Q3 earnings of $0.18 per share, exceeding the Zacks Consensus Estimate of $0.11 per share and significantly higher than $0.05 a year ago. Despite missing revenue estimates for the quarter with $661.66 million, the company has outperformed the S&P 500, with …

Vestis reports Q3 2026: Revenue $661.7M, Adj. EBITDA $80.9M, Free Cash Flow raised to $160–170M

Vestis reported its Q3 fiscal 2026 results, showing revenue of $661.7 million and Adjusted EBITDA of $80.9 million. The company generated $47.0 million in Free Cash Flow and raised its full-year 2026 Free Cash Flow outlook to $160.0–$170.0 million. Management attributed these results to …

Vestis (NYSE: VSTS) boosts 2026 free cash flow outlook after Q3 profit jump

Vestis Corporation (NYSE: VSTS) reported strong fiscal third-quarter 2026 results, leading to an increased free cash flow outlook for fiscal year 2026. The company's net income improved to $11.0 million, and Adjusted EBITDA rose to $80.9 million, driven by strategic transformation initiatives, improved pricing, …

[10-Q] Vestis Corp Quarterly Earnings Report

Vestis Corp (VSTS) has released its Quarterly Earnings Report (Form 10-Q) for the period ended July 3, 2026, showing a significant improvement in net income compared to the previous year. The company reported a net income of $11.0 million for the quarter, up from …

Vestis: Fiscal Q3 Earnings Snapshot

This article provides a fiscal Q3 earnings snapshot for Vestis. No further details are available as the article content was empty except for privacy protection information.

Vestis Corp 3Q FY2026: Revenue $661.7M, EPS $0.08— 10-Q Summary

Vestis Corp reported its third-quarter FY2026 results, showing revenue of $661.7 million and diluted EPS of $0.08. Despite a slight revenue decline, the company improved profitability to $11 million net income, attributed to cost actions and a transformation plan aimed at standardizing operations and …

Renaissance Technologies LLC Has $2.17 Million Stake in Prestige Consumer Healthcare Inc. $PBH

Renaissance Technologies LLC significantly reduced its stake in Prestige Consumer Healthcare Inc. (PBH) by 62% in the first quarter, selling 59,900 shares but retaining 36,702 shares valued at approximately $2.17 million. Despite this, institutional investors collectively own 99.95% of PBH. Prestige Consumer Healthcare reported …

Quantinno Capital Management LP Acquires 19,281 Shares of Prestige Consumer Healthcare Inc. $PBH

Quantinno Capital Management LP significantly increased its stake in Prestige Consumer Healthcare Inc. (PBH) by acquiring 19,281 shares, bringing its total holdings to 36,990 shares valued at $2.19 million. Institutional investors collectively own 99.95% of PBH. The company also surpassed quarterly earnings expectations, reporting …

CELESTICA INC. : SCOTIABANK RESUMES COVERAGE WITH SECTOR OUTPERFORM RATING; TARGET PRICE $500

Scotiabank has resumed coverage on Celestica Inc. (CLS.N) with a "Sector Outperform" rating and set a target price of $500. This news was reported by Reuters on August 11, 2026. The article reiterates this key financial analyst update without further elaboration.